These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8991034)

  • 1. [Causes of death in patients with medullary cancer of the thyroid. GETC. Groupe d'Etude des Tumeurs à Calcitonine].
    Cohen R; Buchsenschutz B; Estrade P; Gardet P; Modigliani E
    Presse Med; 1996 Nov; 25(37):1819-22. PubMed ID: 8991034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d'Etude des Tumeurs á Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons.
    Kraimps JL; Denizot A; Carnaille B; Henry JF; Proye C; Bacourt F; Sarfati E; Dupond JL; Maes B; Travagli JP; Boneu A; Roger P; Houdent C; Barbier J; Modigliani E
    World J Surg; 1996 Sep; 20(7):808-12; discussion 812-3. PubMed ID: 8678955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.
    Modigliani E; Cohen R; Campos JM; Conte-Devolx B; Maes B; Boneu A; Schlumberger M; Bigorgne JC; Dumontier P; Leclerc L; Corcuff B; Guilhem I
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):265-73. PubMed ID: 9578814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Medullary thyroid carcinoma: evolution of concepts].
    Franc B; Modigliani E
    Arch Anat Cytol Pathol; 1998; 46(1-2):100-11. PubMed ID: 9754365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medullary thyroid carcinoma: search for histological predictors of survival (109 proband cases analysis).
    Franc B; Rosenberg-Bourgin M; Caillou B; Dutrieux-Berger N; Floquet J; Houcke-Lecomte M; Justrabo E; Lange F; Labat-Moleur F; Le Bodic MF; Patey M; Beauchet A; Saint-André JP; Hejblum G; Viennet G
    Hum Pathol; 1998 Oct; 29(10):1078-84. PubMed ID: 9781645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).
    Cohen R; Campos JM; Salaün C; Heshmati HM; Kraimps JL; Proye C; Sarfati E; Henry JF; Niccoli-Sire P; Modigliani E
    J Clin Endocrinol Metab; 2000 Feb; 85(2):919-22. PubMed ID: 10690910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical analysis of histomorphological findings in medullary thyroid carcinoma: distinction between the different familial forms of the disease. G.E.T.C. Groupe d'Etude des Tumeurs a Calcitonine.
    Franc B; Rosenberg-Bourgin M; Auvert B; Caillou B; Dutrieux-Berger N; Floquet J; Houcke-Lecomte M; Justrabo E; Labat-Moleur F; Le Bodic MF
    Henry Ford Hosp Med J; 1992; 40(3-4):261-3. PubMed ID: 1362419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).
    Nocera M; Baudin E; Pellegriti G; Cailleux AF; Mechelany-Corone C; Schlumberger M
    Br J Cancer; 2000 Sep; 83(6):715-8. PubMed ID: 10952773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic variables and calcitonin in medullary thyroid cancer.
    Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
    Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
    Schlumberger M; Abdelmoumene N; Delisle MJ; Couette JE
    Br J Cancer; 1995 Feb; 71(2):363-5. PubMed ID: 7530987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986.
    Girelli ME; Nacamulli D; Pelizzo MR; De Vido D; Mian C; Piccolo M; Busnardo B
    Thyroid; 1998 Jun; 8(6):517-23. PubMed ID: 9669290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary medullary thyroid carcinoma: genetic annalysis of three related syndromes. Groupe d'Etude des Tumeurs a Calcitonine.
    Sobol H; Narod SA; Schuffenecker I; Amos C; Ezekowitz RA; Lenoir GM
    Henry Ford Hosp Med J; 1989; 37(3-4):109-11. PubMed ID: 2576938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prognosis of medullary thyroid carcinoma.
    Rendl G; Manzl M; Hitzl W; Sungler P; Pirich C
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):497-505. PubMed ID: 18331612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation.
    Milos IN; Frank-Raue K; Wohllk N; Maia AL; Pusiol E; Patocs A; Robledo M; Biarnes J; Barontini M; Links TP; de Groot JW; Dvorakova S; Peczkowska M; Rybicki LA; Sullivan M; Raue F; Zosin I; Eng C; Neumann HP
    Endocr Relat Cancer; 2008 Dec; 15(4):1035-41. PubMed ID: 18794325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines.
    Rohmer V; Vidal-Trecan G; Bourdelot A; Niccoli P; Murat A; Wemeau JL; Borson-Chazot F; Schvartz C; Tabarin A; Chabre O; Chabrier G; Caron P; Rodien P; Schlumberger M; Baudin E;
    J Clin Endocrinol Metab; 2011 Mar; 96(3):E509-18. PubMed ID: 21190982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes.
    Skinner MA; Wells SA
    Semin Pediatr Surg; 1997 Aug; 6(3):134-40. PubMed ID: 9263335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection of hereditary medullary thyroid cancer with polymorphic DNA probes. Groupe d'Etude des Tumeurs a Calcitonine.
    Narod SA; Sobol H; Schuffenecker I; Ezekowitz RA; Lenoir GM
    Henry Ford Hosp Med J; 1989; 37(3-4):106-8. PubMed ID: 2576937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B.
    O'Riordain DS; O'Brien T; Weaver AL; Gharib H; Hay ID; Grant CS; van Heerden JA
    Surgery; 1994 Dec; 116(6):1017-23. PubMed ID: 7985081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer.
    Kandil E; Gilson MM; Alabbas HH; Tufaro AP; Dackiw A; Tufano RP
    Ann Surg Oncol; 2011 Apr; 18(4):1028-34. PubMed ID: 21046269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.